More articles from From the Editor
- The search for precision
The day may come soon when we get EMR alerts if we try to prescribe certain drugs to patients with certain gene variants.
- Modifying genetic diseases: Promises to be realized?
Genetic engineering offers hope to patients and families who previously had little.
- Off-label and oft-prescribed
When prescribing drugs for uses beyond their FDA indications, we need to explain their anticipated side effects and benefits.
- A link between A-fib and sleep apnea is no surprise, but why?
The two conditions commonly coexist, and treating the sleep apnea results in better rhythm-directed outcomes in the A-fib.
- A few pearls can help prepare the mind
The caregiver with a prepared mind is more likely to experience the diagnostic epiphany.
- Clinical outcomes in diabetes: It’s not just the glucose (and it’s not so simple)
As we dig deeper into the reduction in cardiovascular deaths seen with some newer drugs, several questions arise.
- Deciding when a picture is worth a thousand words and several thousand dollars
Physical examination is cheap but not highly reproducible. Imaging is expensive but may be more sensitive and specific.
- Clinical trials: More to learn than the results
The details of the GIACTA trial challenge and reaffirm some of our clinical impressions about giant cell arteritis.
- The return of measles—an unnecessary sequel
Why are we having such a tough time convincing people to get routine vaccines for themselves and for their kids?
- Infection or not infection, that is the question—Is procalcitonin the answer?
What is different about procalcitonin that allows it to succeed as a biomarker where CRP and the ESR have failed?